The artificial intelligence health care market is expected to grow by more than 500% from $29bn in 2024 to $187bn by 2030, and could bring much value to the pharma industry by streamlining drug discovery, clinical trials, and supply chain management, according to a report from global consulting firm Berkeley Research Group (BRG).
Despite these impressive predictions, BRG noted in its ‘AI and the Future of Healthcare’ report that uptake of AI has been slower in the pharmaceutical industry than other areas of...